146 related articles for article (PubMed ID: 8048526)
1. Biliary excretion of plasma non-transferrin-bound iron in rats: pathogenetic importance in iron-overload disorders.
Brissot P; Zanninelli G; Guyader D; Zeind J; Gollan J
Am J Physiol; 1994 Jul; 267(1 Pt 1):G135-42. PubMed ID: 8048526
[TBL] [Abstract][Full Text] [Related]
2. Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats.
Zanninelli G; Choudury R; Loréal O; Guyader D; Lescoat G; Arnaud J; Verna R; Cosson B; Singh S; Hider RC; Brissot P
J Hepatol; 1997 Jul; 27(1):176-84. PubMed ID: 9252093
[TBL] [Abstract][Full Text] [Related]
3. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats.
Brissot P; Bolder U; Schteingart CD; Arnaud J; Hofmann AF
Hepatology; 1997 Jun; 25(6):1457-61. PubMed ID: 9185768
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
5. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
Kontoghiorghes GJ; Barr J; Nortey P; Sheppard L
Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
[TBL] [Abstract][Full Text] [Related]
6. Biliary excretion of iron from hepatocyte lysosomes in the rat. A major excretory pathway in experimental iron overload.
LeSage GD; Kost LJ; Barham SS; LaRusso NF
J Clin Invest; 1986 Jan; 77(1):90-7. PubMed ID: 3944262
[TBL] [Abstract][Full Text] [Related]
7. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
Cikrt M; Ponka P; Necas E; Neuwirt J
Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
[TBL] [Abstract][Full Text] [Related]
8. Mobilization of iron by chiral and achiral anionic 3-hydroxypyrid-4-ones.
Molenda JJ; Jones MM; Johnston DS; Walker EM; Cannon DJ
J Med Chem; 1994 Dec; 37(25):4363-70. PubMed ID: 7996548
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Bergeron RJ; Streiff RR; Wiegand J; Luchetta G; Creary EA; Peter HH
Blood; 1992 Apr; 79(7):1882-90. PubMed ID: 1558978
[TBL] [Abstract][Full Text] [Related]
10. The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue.
Yokel RA; Fredenburg AM; Durbin PW; Xu J; Rayens MK; Raymond KN
J Pharm Sci; 2000 Apr; 89(4):545-55. PubMed ID: 10737916
[TBL] [Abstract][Full Text] [Related]
11. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Florence A; Ward RJ; Peters TJ; Crichton RR
Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
[TBL] [Abstract][Full Text] [Related]
12. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
Bláha K; Cikrt M; Nerudová J; Ponka HF
Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
[TBL] [Abstract][Full Text] [Related]
13. Acute infusions of bile salts increase biliary excretion of iron in iron-loaded rats.
Lévy P; Dumont M; Brissot P; Letreut A; Favier A; Deugnier Y; Erlinger S
Gastroenterology; 1991 Dec; 101(6):1673-9. PubMed ID: 1955132
[TBL] [Abstract][Full Text] [Related]
14. Enhanced biliary iron excretion with amphiphilic diethylenetriaminepentaacetic acid.
Adams PC; Lin E; Barber KR; Grant CW
Hepatology; 1991 Dec; 14(6):1230-4. PubMed ID: 1959873
[TBL] [Abstract][Full Text] [Related]
15. Iron absorption and biliary excretion of transferrin in rats.
Schümann K; Schäfer SG; Forth W
Res Exp Med (Berl); 1986; 186(3):215-9. PubMed ID: 3738220
[TBL] [Abstract][Full Text] [Related]
16. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
17. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
Link G; Pinson A; Hershko C
Blood; 1994 May; 83(9):2692-7. PubMed ID: 8167347
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
Gyparaki M; Porter JB; Hirani S; Streater M; Hider RC; Huehns ER
Acta Haematol; 1987; 78(2-3):217-21. PubMed ID: 3120475
[TBL] [Abstract][Full Text] [Related]
19. Biliary excretion of lysosomal enzymes, iron, and oxidized protein in Fischer-344 and Sprague-Dawley rats and the effects of diquat and acetaminophen.
Gupta S; Rogers LK; Smith CV
Toxicol Appl Pharmacol; 1994 Mar; 125(1):42-50. PubMed ID: 8128494
[TBL] [Abstract][Full Text] [Related]
20. Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.
Kontoghiorghes GJ
Acta Haematol; 1987; 78(2-3):212-6. PubMed ID: 3120474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
